Successful Treatment of Severe, Poorly Controlled Benign Essential Blepharospasm with DaxibotulinumtoxinA.

Autor:	Shoji MK; Department of Ophthalmology, Shiley Eye Institute, Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego., Sargsyan S; Department of Ophthalmology, UC San Diego School of Medicine, La Jolla, California, USA., Al-Sharif E; Department of Ophthalmology, Shiley Eye Institute, Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego.; Surgery Department, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia., Dib El Jalbout N; Department of Ophthalmology, Shiley Eye Institute, Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego., Korn BS; Department of Ophthalmology, Shiley Eye Institute, Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego., Kikkawa DO; Department of Ophthalmology, Shiley Eye Institute, Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego., Liu CY; Department of Ophthalmology, Shiley Eye Institute, Division of Oculofacial Plastic and Reconstructive Surgery, UC San Diego.
Jazyk:	angličtina
Zdroj:	Ophthalmic plastic and reconstructive surgery [Ophthalmic Plast Reconstr Surg] 2024 Dec 10. Date of Electronic Publication: 2024 Dec 10.
DOI:	10.1097/IOP.0000000000002817
Abstrakt:	Benign essential blepharospasm is a focal dystonia characterized by involuntary contractions of the orbicularis oculi. Botulinum toxin type A injections are often first-line treatment, but patients may experience refractory symptoms or decreased response over time. DaxibotulinumtoxinA, a novel botulinum toxin type A product, has shown promise in cervical dystonia and facial rhytids but has not been previously reported for benign essential blepharospasm treatment. This case highlights a 57-year-old male with severe, poorly controlled benign essential blepharospasm despite high-dose injections of onabotulinumtoxinA and incobotulinumtoxinA. He subsequently received 100 units of daxibotulinumtoxinA in the same periorbital injection pattern with subjective faster onset, extended duration of effect, and improved symptom management compared to previous treatments. Notably, the patient experienced 50% to 75% efficacy retention at 3 months postinjection, significantly better than his response to other botulinum toxin type A products. This case suggests that daxibotulinumtoxinA may be an effective treatment for benign essential blepharospasm including patients experiencing poor symptom control with other botulinum toxin type A products. Competing Interests: M.K.S.: Research supported by the Heed Foundation; C.Y.L.: Principal investigator for Lassen Therapeutics-sponsored clinical trial; Wolters Kluwers Health Royalties; D.O.K. consultant: Horizon Therapeutics, Lassen Therapeutics, Thyroscope, Immunovant; B.S.K. Consultant: Horizon Therapeutics, Immunovant, Elsevier Royalties. Other authors have no conflicts of interest to disclose. (Copyright © 2024 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu